Tonix Pharmaceuticals Holding Stock Return On Equity

TNXP Stock

USD 0.19 0.01 5.00%

Tonix Pharmaceuticals Holding fundamentals help investors to digest information that contributes to Tonix Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Tonix Stock. The fundamental analysis module provides a way to measure Tonix Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tonix Pharmaceuticals stock.

		Last Reported	Projected for Next Year
	Return On Equity	(1.11)	(1.16)

As of 11/23/2024, Return On Equity is likely to drop to -1.16.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Tonix Pharmaceuticals Holding Company Return On Equity Analysis

Tonix Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Return On Equity

Net Income

Total Equity

More About Return On Equity | All Equity Analysis

Current Tonix Pharmaceuticals Return On Equity

-1.63

Most of Tonix Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tonix Pharmaceuticals Holding is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Tonix Return On Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Tonix Pharmaceuticals is extremely important. It helps to project a fair market value of Tonix Stock properly, considering its historical fundamentals such as Return On Equity. Since Tonix Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tonix Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tonix Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Short Term Investments	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Net Tangible Assets	Current Deferred Revenue	Long Term Debt	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Term Debt	Intangible Assets	Property Plant Equipment	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.94	-0.8	-0.84	0.83	0.23	0.73	0.89	0.69	0.88	0.94	0.69	0.68	-0.4	0.91	-0.22	0.5	0.43	0.83	-0.4	0.97	0.8	0.71
Total Stockholder Equity	0.94		-0.92	-0.68	0.85	0.25	0.49	0.96	0.75	0.94	0.8	0.7	0.56	-0.08	0.76	-0.18	0.22	0.14	0.65	-0.08	0.97	0.91	0.76
Net Debt	-0.8	-0.92		0.42	-0.74	-0.17	-0.2	-0.98	-0.86	-0.94	-0.57	-0.55	-0.42	-0.16	-0.55	0.17	0.07	0.16	-0.35	-0.16	-0.86	-0.97	-0.87
Retained Earnings	-0.84	-0.68	0.42		-0.61	-0.27	-0.91	-0.56	-0.36	-0.58	-0.94	-0.51	-0.82	0.69	-0.98	0.34	-0.81	-0.75	-0.93	0.69	-0.73	-0.4	-0.38
Net Receivables	0.83	0.85	-0.74	-0.61		0.13	0.53	0.81	0.69	0.79	0.74	0.82	0.54	-0.17	0.68	-0.18	0.32	0.24	0.62	-0.17	0.85	0.78	0.69
Short Term Investments	0.23	0.25	-0.17	-0.27	0.13		0.15	0.29	0.09	0.28	0.2	0.22	0.11	0.0	0.27	0.53	0.09	0.05	0.1	0.0	0.12	0.1	0.1
Total Liab	0.73	0.49	-0.2	-0.91	0.53	0.15		0.37	0.29	0.41	0.91	0.49	0.68	-0.88	0.89	-0.22	0.95	0.93	0.94	-0.88	0.6	0.23	0.3
Total Current Assets	0.89	0.96	-0.98	-0.56	0.81	0.29	0.37		0.86	0.97	0.7	0.63	0.5	0.0	0.68	-0.11	0.1	0.01	0.49	0.0	0.91	0.96	0.87
Common Stock	0.69	0.75	-0.86	-0.36	0.69	0.09	0.29	0.86		0.88	0.54	0.45	0.43	0.01	0.5	-0.22	0.06	-0.01	0.28	0.01	0.74	0.89	1.0
Accounts Payable	0.88	0.94	-0.94	-0.58	0.79	0.28	0.41	0.97	0.88		0.71	0.61	0.56	-0.03	0.69	-0.17	0.13	0.05	0.51	-0.03	0.91	0.94	0.89
Net Tangible Assets	0.94	0.8	-0.57	-0.94	0.74	0.2	0.91	0.7	0.54	0.71		0.64	0.72	-0.66	0.97	-0.24	0.75	0.7	0.95	-0.66	0.87	0.59	0.55
Current Deferred Revenue	0.69	0.7	-0.55	-0.51	0.82	0.22	0.49	0.63	0.45	0.61	0.64		0.27	-0.18	0.56	0.04	0.33	0.26	0.56	-0.18	0.67	0.55	0.44
Long Term Debt	0.68	0.56	-0.42	-0.82	0.54	0.11	0.68	0.5	0.43	0.56	0.72	0.27		-0.49	0.81	-0.48	0.57	0.52	0.69	-0.49	0.62	0.42	0.46
Long Term Debt Total	-0.4	-0.08	-0.16	0.69	-0.17	0.0	-0.88	0.0	0.01	-0.03	-0.66	-0.18	-0.49		-0.65	0.17	-0.94	-0.95	-0.76	1.0	-0.25	0.13	0.01
Capital Surpluse	0.91	0.76	-0.55	-0.98	0.68	0.27	0.89	0.68	0.5	0.69	0.97	0.56	0.81	-0.65		-0.31	0.75	0.69	0.91	-0.65	0.82	0.54	0.53
Deferred Long Term Liab	-0.22	-0.18	0.17	0.34	-0.18	0.53	-0.22	-0.11	-0.22	-0.17	-0.24	0.04	-0.48	0.17	-0.31		-0.2	-0.18	-0.29	0.17	-0.3	-0.23	-0.24
Short Term Debt	0.5	0.22	0.07	-0.81	0.32	0.09	0.95	0.1	0.06	0.13	0.75	0.33	0.57	-0.94	0.75	-0.2		0.99	0.83	-0.94	0.34	-0.05	0.07
Intangible Assets	0.43	0.14	0.16	-0.75	0.24	0.05	0.93	0.01	-0.01	0.05	0.7	0.26	0.52	-0.95	0.69	-0.18	0.99		0.8	-0.95	0.27	-0.13	-0.01
Property Plant Equipment	0.83	0.65	-0.35	-0.93	0.62	0.1	0.94	0.49	0.28	0.51	0.95	0.56	0.69	-0.76	0.91	-0.29	0.83	0.8		-0.76	0.75	0.38	0.3
Long Term Investments	-0.4	-0.08	-0.16	0.69	-0.17	0.0	-0.88	0.0	0.01	-0.03	-0.66	-0.18	-0.49	1.0	-0.65	0.17	-0.94	-0.95	-0.76		-0.25	0.13	0.01
Net Invested Capital	0.97	0.97	-0.86	-0.73	0.85	0.12	0.6	0.91	0.74	0.91	0.87	0.67	0.62	-0.25	0.82	-0.3	0.34	0.27	0.75	-0.25		0.89	0.76
Net Working Capital	0.8	0.91	-0.97	-0.4	0.78	0.1	0.23	0.96	0.89	0.94	0.59	0.55	0.42	0.13	0.54	-0.23	-0.05	-0.13	0.38	0.13	0.89		0.9
Capital Stock	0.71	0.76	-0.87	-0.38	0.69	0.1	0.3	0.87	1.0	0.89	0.55	0.44	0.46	0.01	0.53	-0.24	0.07	-0.01	0.3	0.01	0.76	0.9

Click cells to compare fundamentals

For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.

Competition

Predict Tonix Pharmaceuticals

Return On Equity Over Time

Tonix Total Stockholder Equity

Total Stockholder Equity

53.87 Million

At this time, Tonix Pharmaceuticals' Total Stockholder Equity is relatively stable compared to the past year.

Based on the latest financial disclosure, Tonix Pharmaceuticals Holding has a Return On Equity of -1.6324. This is 93.19% lower than that of the Biotechnology sector and 95.52% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.

Tonix Return On Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tonix Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tonix Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tonix Pharmaceuticals by comparing valuation metrics of similar companies.

Tonix Pharmaceuticals is currently under evaluation in return on equity category among its peers.

Tonix Fundamentals

	Return On Equity	-1.63
	Return On Asset	-0.52
	Operating Margin	(8.31) %
	Current Valuation	15.97 M
	Shares Outstanding	186.89 M
	Shares Owned By Insiders	0.16 %
	Shares Owned By Institutions	0.23 %
	Number Of Shares Shorted	7.67 M
	Price To Earning	(0.69) X
	Price To Book	0.48 X
	Price To Sales	2.85 X
	Revenue	7.77 M
	EBITDA	(114.09 M)
	Net Income	(116.66 M)
	Cash And Equivalents	145.48 M
	Cash Per Share	3.38 X
	Total Debt	9.81 M
	Debt To Equity	0 %
	Current Ratio	12.05 X
	Book Value Per Share	57.61 X
	Cash Flow From Operations	(102 M)
	Short Ratio	0.35 X
	Earnings Per Share	(80.39) X
	Target Price	21.0
	Number Of Employees	103
	Beta	2.08
	Market Capitalization	35.51 M
	Total Asset	154.46 M
	Retained Earnings	(600.66 M)
	Working Capital	28.88 M
	Current Asset	46.36 M
	Current Liabilities	6.65 M
	Net Asset	154.46 M

About Tonix Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Tonix Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tonix Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tonix Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Tonix Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tonix Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tonix Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Tonix Stock

0.61

VALN

Valneva SE ADR

Pair Corr

Moving against Tonix Stock

0.63

NXGLW

NexGel Warrant

Pair Corr

The ability to find closely correlated positions to Tonix Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tonix Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tonix Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tonix Pharmaceuticals Holding to buy it.

The correlation of Tonix Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tonix Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tonix Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Tonix Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Tonix Stock Analysis

When running Tonix Pharmaceuticals' price analysis, check to measure Tonix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tonix Pharmaceuticals is operating at the current time. Most of Tonix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tonix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tonix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tonix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC